Lai Kai Pharmaceutical-B (02105.HK) has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) for its proprietary therapeutic, LAE103. LAE103, a monoclonal antibody specifically targeting ActRIIB, is designed to address sarcopenic obesity and associated myopathies. The company aims to assess the efficacy and safety of monoclonal antibodies targeting both ActRIIA and ActRIIB receptors in human subjects, with the goal of offering tailored therapeutic options for patients suffering from metabolic disorders.